KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Treasury Shares (2018 - 2026)

Pacific Biosciences Of California has reported Treasury Shares over the past 8 years, most recently at $392000.0 for Q4 2025.

  • For Q4 2025, Treasury Shares fell 97.24% year-over-year to $392000.0; the TTM value through Dec 2025 reached $392000.0, down 97.24%, while the annual FY2025 figure was $392000.0, 97.24% down from the prior year.
  • Treasury Shares for Q4 2025 was $392000.0 at Pacific Biosciences Of California, roughly flat from $392000.0 in the prior quarter.
  • Over five years, Treasury Shares peaked at $21.4 million in Q1 2025 and troughed at $8392.0 in Q2 2022.
  • A 5-year average of $6.3 million and a median of $6.5 million in 2021 define the central range for Treasury Shares.
  • Biggest five-year swings in Treasury Shares: tumbled 99.88% in 2022 and later skyrocketed 150555.39% in 2023.
  • Year by year, Treasury Shares stood at $7.4 million in 2021, then increased by 15.46% to $8.5 million in 2022, then tumbled by 93.66% to $541000.0 in 2023, then surged by 2526.8% to $14.2 million in 2024, then tumbled by 97.24% to $392000.0 in 2025.
  • Business Quant data shows Treasury Shares for PACB at $392000.0 in Q4 2025, $392000.0 in Q3 2025, and $392000.0 in Q2 2025.